Anavex Life Sciences Corp. (AVXL)

Anavex Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Selling, General & Admin	12.8	13.82	11.04	12.05	13.07	9.02
Research & Development	36.46	37.59	41.84	43.72	37.92	32.98
Total Operating Expenses	49.25	51.41	52.88	55.76	50.99	42
Operating Income	-44.6	-51.41	-52.88	-55.76	-50.99	-42
Interest Income	4.66	5.36	9.69	9.26	4.27	4.63
Interest Expense	-	-	-	-0.96	-	-
Other Non-Operating Income (Expense)	1.13	-0.33	0.19	-0.04	-0.9	-0.27
Total Non-Operating Income (Expense)	5.79	5.03	9.88	8.26	3.37	4.36
Pretax Income	-5.66	-46.38	-43	-47.51	-47.62	-37.64
Provision for Income Taxes	0.04	-	-	-	-	-
Net Income	-5.68	-46.38	-43	-47.51	-47.62	-37.64
Net Income to Common	-5.68	-46.38	-43	-47.51	-47.62	-37.64
Shares Outstanding (Basic)	86	85	83	80	77	70
Shares Outstanding (Diluted)	86	85	83	80	77	70
Shares Change (YoY)	2.61%	2.18%	4.61%	3.74%	10.18%	19.95%
EPS (Basic)	-0.46	-0.54	-0.52	-0.60	-0.62	-0.54
EPS (Diluted)	-0.46	-0.54	-0.52	-0.60	-0.62	-0.54
Shares Outstanding	92.67	86.67	84.8	82.07	77.94	75.92
Free Cash Flow	-34.08	-39.04	-30.81	-27.79	-24.24	-30.38
Free Cash Flow Per Share	-0.39	-0.46	-0.37	-0.35	-0.32	-0.44
EBITDA	-44.6	-51.41	-52.88	-55.76	-50.99	-42
EBIT	-44.6	-51.41	-52.88	-55.76	-50.99	-42
Effective Tax Rate	-0.64%	0.00%	0.00%	0.00%	0.00%	0.00%

Updated Feb 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q